DALLAS, April 14, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Acute Pain - Pipeline Review, H1 2015" therapeutic market research report of 192 pages with latest updates, data and information to its online business intelligence library.
The report "Acute Pain Pipeline Review, H1 2015" provides an overview of the Acute Pain's therapeutic pipeline.
Pains in medical terms are usually of two kinds- acute and chronic. Acute pain is when a person starts feeling uncomfortable due to a certain pain that is usually sharp in quality. Some of the common reasons of acute pain are Surgery, Broken bones, Dental work, Burns or cuts, Labor and childbirth. This type of pain is usually characterized by severe pains that comes quickly and lasts for very short period of time. Different drugs are being made available for diseases which are known to cause acute pain. There are countries like South Africa where people do not have access to proper medicines as a result they die after suffering unnecessary pain after months and weeks. Medicine companies can explore such regions where there are ample of opportunities.
The aim of the pharmaceutical companies should be to identify the correct agent who knows how to reach put to the end customer. They should be aware of the targeted disease and market accordingly. A large population of the US suffers from the problem of acute pain. Companies targeting this market should be aware of the FDA regulations and strictly follow it to avoid any hassle that may come in the way of their operation.
The report on Acute Pain - Pipeline Review, H1 2015 gives a better understanding of the treatment being meted out in different regions by different institutions. The report includes vital details of different drugs. These are ANAVEX-1519, BBI-11008, CMX-020, DepoNSAID ER, E-52862, FY-101C, GIBH-1014, HS-731, ibuprofen, ketamine hydrochloride, lidocaine, Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain, NKTR-192, Omnitram, Prostatic Acid Phosphatase, RO-656570, SA-14867, TRV-734, U-2902, VPX-595, X-0002, ZEP-3 and many others. This section also includes profiles of different composition of chemicals that's under development and whats the way ahead. The report also covers the profiling of different companies like A. Menarini Industrie Farmaceutiche Riunite Srl, Cara Therapeutics, Inc., Glenmark Pharmaceuticals Ltd., Iroko Pharmaceuticals, LLC, KemPharm, Inc., Laboratorios Del Dr. Esteve S.A., Merck & Co., Inc., Nuvo Research Inc., Orbis Biosciences, Inc., Pacira Pharmaceuticals, Inc., Rottapharm SpA, Santen Pharmaceutical Co., Ltd., Syntrix Biosystems, Inc., Thar Pharmaceuticals, Inc., Yungjin Pharm Ind. Co., Ltd. and others. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310131 . (This is a premium report priced at US$2000 for a single user License.)
The report "Acute Pain - Pipeline Review, H1 2015" covers all the latest news and recent developments in the medication and therapeutic market. It has a list of projects that are dormant and reasons for the same. A person referring to this report will be able to analyse the market condition and understand the way forward. It helps one to build their strategies and counter-strategies to attain the competitive advantage in the market. It helps the reader to identify its competitor and gives a snapshot of the unexplored opportunities in the market. For newcomers and emerging players this information would be highly useful in order to plan its way ahead. The report assists its readers to create a proposal for in-licensing and out-licensing strategies, companies looking forward for merger and acquisition will also find this report very useful. To summarize we can say that report provides a detailed assessment of all pipeline projects ie for monotherapy as well as combination therapy. It provides a snapshot of the global therapeutic landscape of Acute Pain.
Global Markets Direct's report on Acute Pain has been compiled from personal databases of the Global Markets Direct, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Many other medical papers have been screened and the data extracted therein has been collated together as the report.
Explore more reports on Pain Management at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/pain-management .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
SOURCE RnR Market Research
Share this article